

1 A bill to be entitled
 2 An act relating to pharmaceutical products containing
 3 cannabis; amending s. 893.03, F.S.; excluding from
 4 Schedule I cannabis if it is contained within a
 5 pharmaceutical product approved by the United States
 6 Food and Drug Administration; providing an effective
 7 date.

8
 9 Be It Enacted by the Legislature of the State of Florida:

10
 11 Section 1. Paragraph (c) of subsection (1) of section
 12 893.03, Florida Statutes, is amended to read:

13 893.03 Standards and schedules.—The substances enumerated
 14 in this section are controlled by this chapter. The controlled
 15 substances listed or to be listed in Schedules I, II, III, IV,
 16 and V are included by whatever official, common, usual,
 17 chemical, trade name, or class designated. The provisions of
 18 this section shall not be construed to include within any of the
 19 schedules contained in this section any excluded drugs listed
 20 within the purview of 21 C.F.R. s. 1308.22, styled "Excluded
 21 Substances"; 21 C.F.R. s. 1308.24, styled "Exempt Chemical
 22 Preparations"; 21 C.F.R. s. 1308.32, styled "Exempted
 23 Prescription Products"; or 21 C.F.R. s. 1308.34, styled "Exempt
 24 Anabolic Steroid Products."

25 (1) SCHEDULE I.—A substance in Schedule I has a high

26 | potential for abuse and has no currently accepted medical use in
27 | treatment in the United States and in its use under medical
28 | supervision does not meet accepted safety standards. The
29 | following substances are controlled in Schedule I:

30 | (c) Unless specifically excepted or unless listed in
31 | another schedule, any material, compound, mixture, or
32 | preparation that contains any quantity of the following
33 | hallucinogenic substances or that contains any of their salts,
34 | isomers, including optical, positional, or geometric isomers,
35 | homologues, nitrogen-heterocyclic analogs, esters, ethers, and
36 | salts of isomers, homologues, nitrogen-heterocyclic analogs,
37 | esters, or ethers, if the existence of such salts, isomers, and
38 | salts of isomers is possible within the specific chemical
39 | designation or class description:

- 40 | 1. Alpha-Ethyltryptamine.
- 41 | 2. 4-Methylaminorex (2-Amino-4-methyl-5-phenyl-2-
42 | oxazoline).
- 43 | 3. Aminorex (2-Amino-5-phenyl-2-oxazoline).
- 44 | 4. DOB (4-Bromo-2,5-dimethoxyamphetamine).
- 45 | 5. 2C-B (4-Bromo-2,5-dimethoxyphenethylamine).
- 46 | 6. Bufotenine.
- 47 | 7. Cannabis, except if it is contained within a
48 | pharmaceutical product approved by the United States Food and
49 | Drug Administration.
- 50 | 8. Cathinone.

- 51 | 9. DET (Diethyltryptamine).
- 52 | 10. 2,5-Dimethoxyamphetamine.
- 53 | 11. DOET (4-Ethyl-2,5-Dimethoxyamphetamine).
- 54 | 12. DMT (Dimethyltryptamine).
- 55 | 13. PCE (N-Ethyl-1-phenylcyclohexylamine) (Ethylamine
- 56 | analog of phencyclidine).
- 57 | 14. JB-318 (N-Ethyl-3-piperidyl benzilate).
- 58 | 15. N-Ethylamphetamine.
- 59 | 16. Fenethylamine.
- 60 | 17. 3,4-Methylenedioxy-N-hydroxyamphetamine.
- 61 | 18. Ibogaine.
- 62 | 19. LSD (Lysergic acid diethylamide).
- 63 | 20. Mescaline.
- 64 | 21. Methcathinone.
- 65 | 22. 5-Methoxy-3,4-methylenedioxyamphetamine.
- 66 | 23. PMA (4-Methoxyamphetamine).
- 67 | 24. PMMA (4-Methoxymethamphetamine).
- 68 | 25. DOM (4-Methyl-2,5-dimethoxyamphetamine).
- 69 | 26. MDEA (3,4-Methylenedioxy-N-ethylamphetamine).
- 70 | 27. MDA (3,4-Methylenedioxyamphetamine).
- 71 | 28. JB-336 (N-Methyl-3-piperidyl benzilate).
- 72 | 29. N,N-Dimethylamphetamine.
- 73 | 30. Parahexyl.
- 74 | 31. Peyote.
- 75 | 32. PCPY (N-(1-Phenylcyclohexyl)-pyrrolidine) (Pyrrolidine

- 76 | analog of phencyclidine).
- 77 | 33. Psilocybin.
- 78 | 34. Psilocyn.
- 79 | 35. *Salvia divinorum*, except for any drug product approved
- 80 | by the United States Food and Drug Administration which contains
- 81 | *Salvia divinorum* or its isomers, esters, ethers, salts, and
- 82 | salts of isomers, esters, and ethers, if the existence of such
- 83 | isomers, esters, ethers, and salts is possible within the
- 84 | specific chemical designation.
- 85 | 36. Salvinorin A, except for any drug product approved by
- 86 | the United States Food and Drug Administration which contains
- 87 | Salvinorin A or its isomers, esters, ethers, salts, and salts of
- 88 | isomers, esters, and ethers, if the existence of such isomers,
- 89 | esters, ethers, and salts is possible within the specific
- 90 | chemical designation.
- 91 | 37. Xylazine.
- 92 | 38. TCP (1-[1-(2-Thienyl)-cyclohexyl]-piperidine)
- 93 | (Thiophene analog of phencyclidine).
- 94 | 39. 3,4,5-Trimethoxyamphetamine.
- 95 | 40. Methyldone (3,4-Methylenedioxyamphetaminone).
- 96 | 41. MDPV (3,4-Methylenedioxypropylamphetamine).
- 97 | 42. Methyldone.
- 98 | 43. Methoxyamphetaminone.
- 99 | 44. Fluoromethyldone.
- 100 | 45. Methylethylamphetaminone.

- 101 46. CP 47,497 (2-(3-Hydroxycyclohexyl)-5-(2-methyloctan-2-
 102 yl)phenol) and its dimethyloctyl (C8) homologue.
- 103 47. HU-210 [(6aR,10aR)-9-(Hydroxymethyl)-6,6-dimethyl-3-
 104 (2-methyloctan-2-yl)-6a,7,10,10a-tetrahydrobenzo[c]chromen-1-
 105 ol].
- 106 48. JWH-018 (1-Pentyl-3-(1-naphthoyl)indole).
- 107 49. JWH-073 (1-Butyl-3-(1-naphthoyl)indole).
- 108 50. JWH-200 (1-[2-(4-Morpholinyl)ethyl]-3-(1-
 109 naphthoyl)indole).
- 110 51. BZP (Benzylpiperazine).
- 111 52. Fluorophenylpiperazine.
- 112 53. Methylphenylpiperazine.
- 113 54. Chlorophenylpiperazine.
- 114 55. Methoxyphenylpiperazine.
- 115 56. DBZP (1,4-Dibenzylpiperazine).
- 116 57. TFMPP (Trifluoromethylphenylpiperazine).
- 117 58. MBDB (Methylbenzodioxolylbutanamine) or (3,4-
 118 Methylenedioxy-N-methylbutanamine).
- 119 59. 5-Hydroxy-AMT (5-Hydroxy-alpha-methyltryptamine).
- 120 60. 5-Hydroxy-N-methyltryptamine.
- 121 61. 5-MeO-MiPT (5-Methoxy-N-methyl-N-isopropyltryptamine).
- 122 62. 5-MeO-AMT (5-Methoxy-alpha-methyltryptamine).
- 123 63. Methyltryptamine.
- 124 64. 5-MeO-DMT (5-Methoxy-N,N-dimethyltryptamine).
- 125 65. 5-Me-DMT (5-Methyl-N,N-dimethyltryptamine).

- 126 | 66. Tyramine (4-Hydroxyphenethylamine).
- 127 | 67. 5-MeO-DiPT (5-Methoxy-N,N-Diisopropyltryptamine).
- 128 | 68. DiPT (N,N-Diisopropyltryptamine).
- 129 | 69. DPT (N,N-Dipropyltryptamine).
- 130 | 70. 4-Hydroxy-DiPT (4-Hydroxy-N,N-diisopropyltryptamine).
- 131 | 71. 5-MeO-DALT (5-Methoxy-N,N-Diallyltryptamine).
- 132 | 72. DOI (4-Iodo-2,5-dimethoxyamphetamine).
- 133 | 73. DOC (4-Chloro-2,5-dimethoxyamphetamine).
- 134 | 74. 2C-E (4-Ethyl-2,5-dimethoxyphenethylamine).
- 135 | 75. 2C-T-4 (4-Isopropylthio-2,5-dimethoxyphenethylamine).
- 136 | 76. 2C-C (4-Chloro-2,5-dimethoxyphenethylamine).
- 137 | 77. 2C-T (4-Methylthio-2,5-dimethoxyphenethylamine).
- 138 | 78. 2C-T-2 (4-Ethylthio-2,5-dimethoxyphenethylamine).
- 139 | 79. 2C-T-7 (4-(n)-Propylthio-2,5-dimethoxyphenethylamine).
- 140 | 80. 2C-I (4-Iodo-2,5-dimethoxyphenethylamine).
- 141 | 81. Butylone (3,4-Methylenedioxy-alpha-
- 142 | methylaminobutyrophenone).
- 143 | 82. Ethcathinone.
- 144 | 83. Ethylone (3,4-Methylenedioxy-N-ethylcathinone).
- 145 | 84. Naphyrone (Naphthylpyrovalerone).
- 146 | 85. Dimethylone (3,4-Methylenedioxy-N,N-
- 147 | dimethylcathinone).
- 148 | 86. 3,4-Methylenedioxy-N,N-diethylcathinone.
- 149 | 87. 3,4-Methylenedioxy-propiofenone.
- 150 | 88. 3,4-Methylenedioxy-alpha-bromopropiofenone.

- 151 | 89. 3,4-Methylenedioxy-propiofenone-2-oxime.
- 152 | 90. 3,4-Methylenedioxy-N-acetylcathinone.
- 153 | 91. 3,4-Methylenedioxy-N-acetylmethcathinone.
- 154 | 92. 3,4-Methylenedioxy-N-acetylethcathinone.
- 155 | 93. Bromomethcathinone.
- 156 | 94. Buphedrone (alpha-Methylamino-butyrophenone).
- 157 | 95. Eutylone (3,4-Methylenedioxy-alpha-
- 158 | ethylaminobutyrophenone).
- 159 | 96. Dimethylcathinone.
- 160 | 97. Dimethylmethcathinone.
- 161 | 98. Pentylone (3,4-Methylenedioxy-alpha-
- 162 | methylaminovalerophenone).
- 163 | 99. MDPPP (3,4-Methylenedioxy-alpha-
- 164 | pyrrolidinopropiofenone).
- 165 | 100. MDPBP (3,4-Methylenedioxy-alpha-
- 166 | pyrrolidinobutyrophenone).
- 167 | 101. MOPPP (Methoxy-alpha-pyrrolidinopropiofenone).
- 168 | 102. MPHP (Methyl-alpha-pyrrolidinohexanophenone).
- 169 | 103. BTCP (Benzothiophenylcyclohexylpiperidine) or BCP
- 170 | (Benocyclidine).
- 171 | 104. F-MABP (Fluoromethylaminobutyrophenone).
- 172 | 105. MeO-PBP (Methoxypyrrolidinobutyrophenone).
- 173 | 106. Et-PBP (Ethylpyrrolidinobutyrophenone).
- 174 | 107. 3-Me-4-MeO-MCAT (3-Methyl-4-Methoxymethcathinone).
- 175 | 108. Me-EABP (Methylethylaminobutyrophenone).

- 176 | 109. Etizolam.
- 177 | 110. PPP (Pyrrolidinopropiophenone).
- 178 | 111. PBP (Pyrrolidinobutyrophenone).
- 179 | 112. PVP (Pyrrolidinovalerophenone) or
- 180 | (Pyrrolidinopentiophenone).
- 181 | 113. MPPP (Methyl-alpha-pyrrolidinopropiophenone).
- 182 | 114. JWH-007 (1-Pentyl-2-methyl-3-(1-naphthoyl)indole).
- 183 | 115. JWH-015 (1-Propyl-2-methyl-3-(1-naphthoyl)indole).
- 184 | 116. JWH-019 (1-Hexyl-3-(1-naphthoyl)indole).
- 185 | 117. JWH-020 (1-Heptyl-3-(1-naphthoyl)indole).
- 186 | 118. JWH-072 (1-Propyl-3-(1-naphthoyl)indole).
- 187 | 119. JWH-081 (1-Pentyl-3-(4-methoxy-1-naphthoyl)indole).
- 188 | 120. JWH-122 (1-Pentyl-3-(4-methyl-1-naphthoyl)indole).
- 189 | 121. JWH-133 ((6aR,10aR)-6,6,9-Trimethyl-3-(2-
- 190 | methylpentan-2-yl)-6a,7,10,10a-tetrahydrobenzo[c]chromene).
- 191 | 122. JWH-175 (1-Pentyl-3-(1-naphthylmethyl)indole).
- 192 | 123. JWH-201 (1-Pentyl-3-(4-methoxyphenylacetyl)indole).
- 193 | 124. JWH-203 (1-Pentyl-3-(2-chlorophenylacetyl)indole).
- 194 | 125. JWH-210 (1-Pentyl-3-(4-ethyl-1-naphthoyl)indole).
- 195 | 126. JWH-250 (1-Pentyl-3-(2-methoxyphenylacetyl)indole).
- 196 | 127. JWH-251 (1-Pentyl-3-(2-methylphenylacetyl)indole).
- 197 | 128. JWH-302 (1-Pentyl-3-(3-methoxyphenylacetyl)indole).
- 198 | 129. JWH-398 (1-Pentyl-3-(4-chloro-1-naphthoyl)indole).
- 199 | 130. HU-211 ((6aS,10aS)-9-(Hydroxymethyl)-6,6-dimethyl-3-
- 200 | (2-methyloctan-2-yl)-6a,7,10,10a-tetrahydrobenzo[c]chromen-1-

HB 1345

2021

201 ol) .

202 131. HU-308 ([(1R,2R,5R)-2-[2,6-Dimethoxy-4-(2-

203 methyloctan-2-yl)phenyl]-7,7-dimethyl-4-bicyclo[3.1.1]hept-3-

204 enyl] methanol) .

205 132. HU-331 (3-Hydroxy-2-[(1R,6R)-3-methyl-6-(1-

206 methylethenyl)-2-cyclohexen-1-yl]-5-pentyl-2,5-cyclohexadiene-

207 1,4-dione) .

208 133. CB-13 (4-Pentyloxy-1-(1-naphthoyl)naphthalene) .

209 134. CB-25 (N-Cyclopropyl-11-(3-hydroxy-5-pentylphenoxy)-

210 undecanamide) .

211 135. CB-52 (N-Cyclopropyl-11-(2-hexyl-5-hydroxyphenoxy)-

212 undecanamide) .

213 136. CP 55,940 (2-[3-Hydroxy-6-propanol-cyclohexyl]-5-(2-

214 methyloctan-2-yl)phenol) .

215 137. AM-694 (1-(5-Fluoropentyl)-3-(2-iodobenzoyl)indole) .

216 138. AM-2201 (1-(5-Fluoropentyl)-3-(1-naphthoyl)indole) .

217 139. RCS-4 (1-Pentyl-3-(4-methoxybenzoyl)indole) .

218 140. RCS-8 (1-(2-Cyclohexylethyl)-3-(2-

219 methoxyphenylacetyl)indole) .

220 141. WIN55,212-2 ((R)-(+)-[2,3-Dihydro-5-methyl-3-(4-

221 morpholinylmethyl)pyrrolo[1,2,3-de]-1,4-benzoxazin-6-yl]-1-

222 naphthalenylmethanone) .

223 142. WIN55,212-3 ([(3S)-2,3-Dihydro-5-methyl-3-(4-

224 morpholinylmethyl)pyrrolo[1,2,3-de]-1,4-benzoxazin-6-yl]-1-

225 naphthalenylmethanone) .

- 226 | 143. Pentedrone (alpha-Methylaminovalerophenone).
 227 | 144. Fluoroamphetamine.
 228 | 145. Fluoromethamphetamine.
 229 | 146. Methoxetamine.
 230 | 147. Methiopropamine.
 231 | 148. Methylbuphedrone (Methyl-alpha-
 232 | methylaminobutyrophenone).
 233 | 149. APB ((2-Aminopropyl)benzofuran).
 234 | 150. APDB ((2-Aminopropyl)-2,3-dihydrobenzofuran).
 235 | 151. UR-144 (1-Pentyl-3-(2,2,3,3-
 236 | tetramethylcyclopropanoyl)indole).
 237 | 152. XLR11 (1-(5-Fluoropentyl)-3-(2,2,3,3-
 238 | tetramethylcyclopropanoyl)indole).
 239 | 153. Chloro UR-144 (1-(Chloropentyl)-3-(2,2,3,3-
 240 | tetramethylcyclopropanoyl)indole).
 241 | 154. AKB48 (N-Adamant-1-yl 1-pentylindazole-3-
 242 | carboxamide).
 243 | 155. AM-2233 (1-[(N-Methyl-2-piperidinyl)methyl]-3-(2-
 244 | iodobenzoyl)indole).
 245 | 156. STS-135 (N-Adamant-1-yl 1-(5-fluoropentyl)indole-3-
 246 | carboxamide).
 247 | 157. URB-597 ((3'-(Aminocarbonyl)[1,1'-biphenyl]-3-yl)-
 248 | cyclohexylcarbamate).
 249 | 158. URB-602 ([1,1'-Biphenyl]-3-yl-carbamic acid,
 250 | cyclohexyl ester).

- 251 | 159. URB-754 (6-Methyl-2-[(4-methylphenyl)amino]-1-
 252 | benzoxazin-4-one).
- 253 | 160. 2C-D (4-Methyl-2,5-dimethoxyphenethylamine).
- 254 | 161. 2C-H (2,5-Dimethoxyphenethylamine).
- 255 | 162. 2C-N (4-Nitro-2,5-dimethoxyphenethylamine).
- 256 | 163. 2C-P (4-(n)-Propyl-2,5-dimethoxyphenethylamine).
- 257 | 164. 25I-NBOMe (4-Iodo-2,5-dimethoxy-[N-(2-
 258 | methoxybenzyl)]phenethylamine).
- 259 | 165. MDMA (3,4-Methylenedioxyamphetamine).
- 260 | 166. PB-22 (8-Quinolinyll 1-pentylindole-3-carboxylate).
- 261 | 167. Fluoro PB-22 (8-Quinolinyll 1-(fluoropentyl)indole-3-
 262 | carboxylate).
- 263 | 168. BB-22 (8-Quinolinyll 1-(cyclohexylmethyl)indole-3-
 264 | carboxylate).
- 265 | 169. Fluoro AKB48 (N-Adamant-1-yl 1-
 266 | (fluoropentyl)indazole-3-carboxamide).
- 267 | 170. AB-PINACA (N-(1-Amino-3-methyl-1-oxobutan-2-yl)-1-
 268 | pentylindazole-3-carboxamide).
- 269 | 171. AB-FUBINACA (N-(1-Amino-3-methyl-1-oxobutan-2-yl)-1-
 270 | (4-fluorobenzyl)indazole-3-carboxamide).
- 271 | 172. ADB-PINACA (N-(1-Amino-3,3-dimethyl-1-oxobutan-2-yl)-
 272 | 1-pentylindazole-3-carboxamide).
- 273 | 173. Fluoro ADBICA (N-(1-Amino-3,3-dimethyl-1-oxobutan-2-
 274 | yl)-1-(fluoropentyl)indole-3-carboxamide).
- 275 | 174. 25B-NBOMe (4-Bromo-2,5-dimethoxy-[N-(2-

HB 1345

2021

276 methoxybenzyl)phenethylamine).

277 175. 25C-NBOMe (4-Chloro-2,5-dimethoxy-[N-(2-

278 methoxybenzyl)phenethylamine).

279 176. AB-CHMINACA (N-(1-Amino-3-methyl-1-oxobutan-2-yl)-1-

280 (cyclohexylmethyl)indazole-3-carboxamide).

281 177. FUB-PB-22 (8-Quinoliny 1-(4-fluorobenzyl)indole-3-

282 carboxylate).

283 178. Fluoro-NNEI (N-Naphthalen-1-yl 1-

284 (fluoropentyl)indole-3-carboxamide).

285 179. Fluoro-AMB (N-(1-Methoxy-3-methyl-1-oxobutan-2-yl)-1-

286 (fluoropentyl)indazole-3-carboxamide).

287 180. THJ-2201 (1-(5-Fluoropentyl)-3-(1-

288 naphthoyl)indazole).

289 181. AM-855 ((4aR,12bR)-8-Hexyl-2,5,5-trimethyl-

290 1,4,4a,8,9,10,11,12b-octahydronaphtho[3,2-c]isochromen-12-ol).

291 182. AM-905 ((6aR,9R,10aR)-3-[(E)-Hept-1-enyl]-9-

292 (hydroxymethyl)-6,6-dimethyl-6a,7,8,9,10,10a-

293 hexahydrobenzo[c]chromen-1-ol).

294 183. AM-906 ((6aR,9R,10aR)-3-[(Z)-Hept-1-enyl]-9-

295 (hydroxymethyl)-6,6-dimethyl-6a,7,8,9,10,10a-

296 hexahydrobenzo[c]chromen-1-ol).

297 184. AM-2389 ((6aR,9R,10aR)-3-(1-Hexyl-cyclobut-1-yl)-

298 6a,7,8,9,10,10a-hexahydro-6,6-dimethyl-6H-dibenzo[b,d]pyran-1,9

299 diol).

300 185. HU-243 ((6aR,8S,9S,10aR)-9-(Hydroxymethyl)-6,6-

HB 1345

2021

301 dimethyl-3-(2-methyloctan-2-yl)-8,9-ditritio-7,8,10,10a-
302 tetrahydro-6aH-benzo[c]chromen-1-ol).

303 186. HU-336 ((6aR,10aR)-6,6,9-Trimethyl-3-pentyl-
304 6a,7,10,10a-tetrahydro-1H-benzo[c]chromene-1,4(6H)-dione).

305 187. MAPB ((2-Methylaminopropyl)benzofuran).

306 188. 5-IT (2-(1H-Indol-5-yl)-1-methyl-ethylamine).

307 189. 6-IT (2-(1H-Indol-6-yl)-1-methyl-ethylamine).

308 190. Synthetic Cannabinoids.—Unless specifically excepted
309 or unless listed in another schedule or contained within a
310 pharmaceutical product approved by the United States Food and
311 Drug Administration, any material, compound, mixture, or
312 preparation that contains any quantity of a synthetic
313 cannabinoid found to be in any of the following chemical class
314 descriptions, or homologues, nitrogen-heterocyclic analogs,
315 isomers (including optical, positional, or geometric), esters,
316 ethers, salts, and salts of homologues, nitrogen-heterocyclic
317 analogs, isomers, esters, or ethers, whenever the existence of
318 such homologues, nitrogen-heterocyclic analogs, isomers, esters,
319 ethers, salts, and salts of isomers, esters, or ethers is
320 possible within the specific chemical class or designation.
321 Since nomenclature of these synthetically produced cannabinoids
322 is not internationally standardized and may continually evolve,
323 these structures or the compounds of these structures shall be
324 included under this subparagraph, regardless of their specific
325 numerical designation of atomic positions covered, if it can be

326 determined through a recognized method of scientific testing or
327 analysis that the substance contains properties that fit within
328 one or more of the following categories:

329 a. Tetrahydrocannabinols.—Any tetrahydrocannabinols
330 naturally contained in a plant of the genus *Cannabis*, the
331 synthetic equivalents of the substances contained in the plant
332 or in the resinous extracts of the genus *Cannabis*, or synthetic
333 substances, derivatives, and their isomers with similar chemical
334 structure and pharmacological activity, including, but not
335 limited to, Delta 9 tetrahydrocannabinols and their optical
336 isomers, Delta 8 tetrahydrocannabinols and their optical
337 isomers, Delta 6a,10a tetrahydrocannabinols and their optical
338 isomers, or any compound containing a tetrahydrobenzo[c]chromene
339 structure with substitution at either or both the 3-position or
340 9-position, with or without substitution at the 1-position with
341 hydroxyl or alkoxy groups, including, but not limited to:

342 (I) Tetrahydrocannabinol.

343 (II) HU-210 ((6aR,10aR)-9-(Hydroxymethyl)-6,6-dimethyl-3-
344 (2-methyloctan-2-yl)-6a,7,10,10a-tetrahydrobenzo[c]chromen-1-
345 ol).

346 (III) HU-211 ((6aS,10aS)-9-(Hydroxymethyl)-6,6-dimethyl-3-
347 (2-methyloctan-2-yl)-6a,7,10,10a-tetrahydrobenzo[c]chromen-1-
348 ol).

349 (IV) JWH-051 ((6aR,10aR)-9-(Hydroxymethyl)-6,6-dimethyl-3-
350 (2-methyloctan-2-yl)-6a,7,10,10a-tetrahydrobenzo[c]chromene).

HB 1345

2021

351 (V) JWH-133 ((6aR,10aR)-6,6,9-Trimethyl-3-(2-methylpentan-
352 2-yl)-6a,7,10,10a-tetrahydrobenzo[c]chromene).

353 (VI) JWH-057 ((6aR,10aR)-6,6,9-Trimethyl-3-(2-methyloctan-
354 2-yl)-6a,7,10,10a-tetrahydrobenzo[c]chromene).

355 (VII) JWH-359 ((6aR,10aR)-1-Methoxy-6,6,9-trimethyl-3-
356 (2,3-dimethylpentan-2-yl)-6a,7,10,10a-
357 tetrahydrobenzo[c]chromene).

358 (VIII) AM-087 ((6aR,10aR)-3-(2-Methyl-6-bromohex-2-yl)-
359 6,6,9-trimethyl-6a,7,10,10a-tetrahydrobenzo[c]chromen-1-ol).

360 (IX) AM-411 ((6aR,10aR)-3-(1-Adamantyl)-6,6,9-trimethyl-
361 6a,7,10,10a-tetrahydrobenzo[c]chromen-1-ol).

362 (X) Parahexyl.

363 b. Naphthoylindoles, Naphthoylindazoles,
364 Naphthoylcarbazoles, Naphthylmethylindoles,
365 Naphthylmethylindazoles, and Naphthylmethylcarbazoles.—Any
366 compound containing a naphthoylindole, naphthoylindazole,
367 naphthoylcarbazole, naphthylmethylindole,
368 naphthylmethylindazole, or naphthylmethylcarbazole structure,
369 with or without substitution on the indole, indazole, or
370 carbazole ring to any extent, whether or not substituted on the
371 naphthyl ring to any extent, including, but not limited to:

372 (I) JWH-007 (1-Pentyl-2-methyl-3-(1-naphthoyl)indole).

373 (II) JWH-011 (1-(1-Methylhexyl)-2-methyl-3-(1-
374 naphthoyl)indole).

375 (III) JWH-015 (1-Propyl-2-methyl-3-(1-naphthoyl)indole).

- 376 (IV) JWH-016 (1-Butyl-2-methyl-3-(1-naphthoyl)indole).
- 377 (V) JWH-018 (1-Pentyl-3-(1-naphthoyl)indole).
- 378 (VI) JWH-019 (1-Hexyl-3-(1-naphthoyl)indole).
- 379 (VII) JWH-020 (1-Heptyl-3-(1-naphthoyl)indole).
- 380 (VIII) JWH-022 (1-(4-Pentenyl)-3-(1-naphthoyl)indole).
- 381 (IX) JWH-071 (1-Ethyl-3-(1-naphthoyl)indole).
- 382 (X) JWH-072 (1-Propyl-3-(1-naphthoyl)indole).
- 383 (XI) JWH-073 (1-Butyl-3-(1-naphthoyl)indole).
- 384 (XII) JWH-080 (1-Butyl-3-(4-methoxy-1-naphthoyl)indole).
- 385 (XIII) JWH-081 (1-Pentyl-3-(4-methoxy-1-naphthoyl)indole).
- 386 (XIV) JWH-098 (1-Pentyl-2-methyl-3-(4-methoxy-1-
- 387 naphthoyl)indole).
- 388 (XV) JWH-116 (1-Pentyl-2-ethyl-3-(1-naphthoyl)indole).
- 389 (XVI) JWH-122 (1-Pentyl-3-(4-methyl-1-naphthoyl)indole).
- 390 (XVII) JWH-149 (1-Pentyl-2-methyl-3-(4-methyl-1-
- 391 naphthoyl)indole).
- 392 (XVIII) JWH-164 (1-Pentyl-3-(7-methoxy-1-
- 393 naphthoyl)indole).
- 394 (XIX) JWH-175 (1-Pentyl-3-(1-naphthylmethyl)indole).
- 395 (XX) JWH-180 (1-Propyl-3-(4-propyl-1-naphthoyl)indole).
- 396 (XXI) JWH-182 (1-Pentyl-3-(4-propyl-1-naphthoyl)indole).
- 397 (XXII) JWH-184 (1-Pentyl-3-[(4-methyl)-1-
- 398 naphthylmethyl]indole).
- 399 (XXIII) JWH-193 (1-[2-(4-Morpholinyl)ethyl]-3-(4-methyl-1-
- 400 naphthoyl)indole).

401 (XXIV) JWH-198 (1-[2-(4-Morpholinyl)ethyl]-3-(4-methoxy-1-
 402 naphthoyl)indole).
 403 (XXV) JWH-200 (1-[2-(4-Morpholinyl)ethyl]-3-(1-
 404 naphthoyl)indole).
 405 (XXVI) JWH-210 (1-Pentyl-3-(4-ethyl-1-naphthoyl)indole).
 406 (XXVII) JWH-387 (1-Pentyl-3-(4-bromo-1-naphthoyl)indole).
 407 (XXVIII) JWH-398 (1-Pentyl-3-(4-chloro-1-
 408 naphthoyl)indole).
 409 (XXIX) JWH-412 (1-Pentyl-3-(4-fluoro-1-naphthoyl)indole).
 410 (XXX) JWH-424 (1-Pentyl-3-(8-bromo-1-naphthoyl)indole).
 411 (XXXI) AM-1220 (1-[(1-Methyl-2-piperidinyl)methyl]-3-(1-
 412 naphthoyl)indole).
 413 (XXXII) AM-1235 (1-(5-Fluoropentyl)-6-nitro-3-(1-
 414 naphthoyl)indole).
 415 (XXXIII) AM-2201 (1-(5-Fluoropentyl)-3-(1-
 416 naphthoyl)indole).
 417 (XXXIV) Chloro JWH-018 (1-(Chloropentyl)-3-(1-
 418 naphthoyl)indole).
 419 (XXXV) Bromo JWH-018 (1-(Bromopentyl)-3-(1-
 420 naphthoyl)indole).
 421 (XXXVI) AM-2232 (1-(4-Cyanobutyl)-3-(1-naphthoyl)indole).
 422 (XXXVII) THJ-2201 (1-(5-Fluoropentyl)-3-(1-
 423 naphthoyl)indazole).
 424 (XXXVIII) MAM-2201 (1-(5-Fluoropentyl)-3-(4-methyl-1-
 425 naphthoyl)indole).

426 (XXXIX) EAM-2201 (1-(5-Fluoropentyl)-3-(4-ethyl-1-
 427 naphthoyl)indole).

428 (XL) EG-018 (9-Pentyl-3-(1-naphthoyl)carbazole).

429 (XLI) EG-2201 (9-(5-Fluoropentyl)-3-(1-
 430 naphthoyl)carbazole).

431 c. Naphthoylpyrroles.—Any compound containing a
 432 naphthoylpyrrole structure, with or without substitution on the
 433 pyrrole ring to any extent, whether or not substituted on the
 434 naphthyl ring to any extent, including, but not limited to:

435 (I) JWH-030 (1-Pentyl-3-(1-naphthoyl)pyrrole).

436 (II) JWH-031 (1-Hexyl-3-(1-naphthoyl)pyrrole).

437 (III) JWH-145 (1-Pentyl-5-phenyl-3-(1-naphthoyl)pyrrole).

438 (IV) JWH-146 (1-Heptyl-5-phenyl-3-(1-naphthoyl)pyrrole).

439 (V) JWH-147 (1-Hexyl-5-phenyl-3-(1-naphthoyl)pyrrole).

440 (VI) JWH-307 (1-Pentyl-5-(2-fluorophenyl)-3-(1-
 441 naphthoyl)pyrrole).

442 (VII) JWH-309 (1-Pentyl-5-(1-naphthalenyl)-3-(1-
 443 naphthoyl)pyrrole).

444 (VIII) JWH-368 (1-Pentyl-5-(3-fluorophenyl)-3-(1-
 445 naphthoyl)pyrrole).

446 (IX) JWH-369 (1-Pentyl-5-(2-chlorophenyl)-3-(1-
 447 naphthoyl)pyrrole).

448 (X) JWH-370 (1-Pentyl-5-(2-methylphenyl)-3-(1-
 449 naphthoyl)pyrrole).

450 d. Naphthylmethylenindenes.—Any compound containing a

451 naphthylmethylenindene structure, with or without substitution
452 at the 3-position of the indene ring to any extent, whether or
453 not substituted on the naphthyl ring to any extent, including,
454 but not limited to, JWH-176 (3-Pentyl-1-
455 (naphthylmethylene)indene).

456 e. Phenylacetylindoles and Phenylacetylindazoles.—Any
457 compound containing a phenylacetylindole or phenylacetylindazole
458 structure, with or without substitution on the indole or
459 indazole ring to any extent, whether or not substituted on the
460 phenyl ring to any extent, including, but not limited to:

- 461 (I) JWH-167 (1-Pentyl-3-(phenylacetyl)indole).
462 (II) JWH-201 (1-Pentyl-3-(4-methoxyphenylacetyl)indole).
463 (III) JWH-203 (1-Pentyl-3-(2-chlorophenylacetyl)indole).
464 (IV) JWH-250 (1-Pentyl-3-(2-methoxyphenylacetyl)indole).
465 (V) JWH-251 (1-Pentyl-3-(2-methylphenylacetyl)indole).
466 (VI) JWH-302 (1-Pentyl-3-(3-methoxyphenylacetyl)indole).
467 (VII) Cannabipiperidiethanone.
468 (VIII) RCS-8 (1-(2-Cyclohexylethyl)-3-(2-
469 methoxyphenylacetyl)indole).

470 f. Cyclohexylphenols.—Any compound containing a
471 cyclohexylphenol structure, with or without substitution at the
472 5-position of the phenolic ring to any extent, whether or not
473 substituted on the cyclohexyl ring to any extent, including, but
474 not limited to:

- 475 (I) CP 47,497 (2-(3-Hydroxycyclohexyl)-5-(2-methyloctan-2-

HB 1345

2021

476 yl)phenol).

477 (II) Cannabicyclohexanol (CP 47,497 dimethyloctyl (C8)
478 homologue).

479 (III) CP-55,940 (2-(3-Hydroxy-6-propanol-cyclohexyl)-5-(2-
480 methyloctan-2-yl)phenol).

481 g. Benzoylindoles and Benzoylindazoles.—Any compound
482 containing a benzoylindole or benzoylindazole structure, with or
483 without substitution on the indole or indazole ring to any
484 extent, whether or not substituted on the phenyl ring to any
485 extent, including, but not limited to:

486 (I) AM-679 (1-Pentyl-3-(2-iodobenzoyl)indole).

487 (II) AM-694 (1-(5-Fluoropentyl)-3-(2-iodobenzoyl)indole).

488 (III) AM-1241 (1-[(N-Methyl-2-piperidinyl)methyl]-3-(2-
489 iodo-5-nitrobenzoyl)indole).

490 (IV) Pravadoline (1-[2-(4-Morpholinyl)ethyl]-2-methyl-3-
491 (4-methoxybenzoyl)indole).

492 (V) AM-2233 (1-[(N-Methyl-2-piperidinyl)methyl]-3-(2-
493 iodobenzoyl)indole).

494 (VI) RCS-4 (1-Pentyl-3-(4-methoxybenzoyl)indole).

495 (VII) RCS-4 C4 homologue (1-Butyl-3-(4-
496 methoxybenzoyl)indole).

497 (VIII) AM-630 (1-[2-(4-Morpholinyl)ethyl]-2-methyl-6-iodo-
498 3-(4-methoxybenzoyl)indole).

499 h. Tetramethylcyclopropanoylindoles and
500 Tetramethylcyclopropanoylindazoles.—Any compound containing a

501 tetramethylcyclopropanoylindole or
502 tetramethylcyclopropanoylindazole structure, with or without
503 substitution on the indole or indazole ring to any extent,
504 whether or not substituted on the tetramethylcyclopropyl group
505 to any extent, including, but not limited to:

506 (I) UR-144 (1-Pentyl-3-(2,2,3,3-
507 tetramethylcyclopropanoyl)indole).

508 (II) XLR11 (1-(5-Fluoropentyl)-3-(2,2,3,3-
509 tetramethylcyclopropanoyl)indole).

510 (III) Chloro UR-144 (1-(Chloropentyl)-3-(2,2,3,3-
511 tetramethylcyclopropanoyl)indole).

512 (IV) A-796,260 (1-[2-(4-Morpholinyl)ethyl]-3-(2,2,3,3-
513 tetramethylcyclopropanoyl)indole).

514 (V) A-834,735 (1-[4-(Tetrahydropyranyl)methyl]-3-(2,2,3,3-
515 tetramethylcyclopropanoyl)indole).

516 (VI) M-144 (1-(5-Fluoropentyl)-2-methyl-3-(2,2,3,3-
517 tetramethylcyclopropanoyl)indole).

518 (VII) FUB-144 (1-(4-Fluorobenzyl)-3-(2,2,3,3-
519 tetramethylcyclopropanoyl)indole).

520 (VIII) FAB-144 (1-(5-Fluoropentyl)-3-(2,2,3,3-
521 tetramethylcyclopropanoyl)indazole).

522 (IX) XLR12 (1-(4,4,4-Trifluorobutyl)-3-(2,2,3,3-
523 tetramethylcyclopropanoyl)indole).

524 (X) AB-005 (1-[(1-Methyl-2-piperidinyl)methyl]-3-(2,2,3,3-
525 tetramethylcyclopropanoyl)indole).

526 i. Adamantoylindoles, Adamantoylindazoles, Adamantylindole
 527 carboxamides, and Adamantylindazole carboxamides.—Any compound
 528 containing an adamantoyl indole, adamantoyl indazole, adamantyl
 529 indole carboxamide, or adamantyl indazole carboxamide structure,
 530 with or without substitution on the indole or indazole ring to
 531 any extent, whether or not substituted on the adamantyl ring to
 532 any extent, including, but not limited to:

533 (I) AKB48 (N-Adamant-1-yl 1-pentylindazole-3-carboxamide).

534 (II) Fluoro AKB48 (N-Adamant-1-yl 1-
 535 (fluoropentyl)indazole-3-carboxamide).

536 (III) STS-135 (N-Adamant-1-yl 1-(5-fluoropentyl)indole-3-
 537 carboxamide).

538 (IV) AM-1248 (1-(1-Methylpiperidine)methyl-3-(1-
 539 adamantoyl)indole).

540 (V) AB-001 (1-Pentyl-3-(1-adamantoyl)indole).

541 (VI) APICA (N-Adamant-1-yl 1-pentylindole-3-carboxamide).

542 (VII) Fluoro AB-001 (1-(Fluoropentyl)-3-(1-
 543 adamantoyl)indole).

544 j. Quinolinylindolecarboxylates,
 545 Quinolinylindazolecarboxylates, Quinolinylindolecarboxamides,
 546 and Quinolinylindazolecarboxamides.—Any compound containing a
 547 quinolinylindole carboxylate, quinolinylindazole carboxylate,
 548 isoquinolinylindole carboxylate, isoquinolinylindazole
 549 carboxylate, quinolinylindole carboxamide, quinolinylindazole
 550 carboxamide, isoquinolinylindole carboxamide, or

551 isoquinolinylindazole carboxamide structure, with or without
552 substitution on the indole or indazole ring to any extent,
553 whether or not substituted on the quinoline or isoquinoline ring
554 to any extent, including, but not limited to:

555 (I) PB-22 (8-Quinoliny 1-pentylindole-3-carboxylate).

556 (II) Fluoro PB-22 (8-Quinoliny 1-(fluoropentyl)indole-3-
557 carboxylate).

558 (III) BB-22 (8-Quinoliny 1-(cyclohexylmethyl)indole-3-
559 carboxylate).

560 (IV) FUB-PB-22 (8-Quinoliny 1-(4-fluorobenzyl)indole-3-
561 carboxylate).

562 (V) NPB-22 (8-Quinoliny 1-pentylindazole-3-carboxylate).

563 (VI) Fluoro NPB-22 (8-Quinoliny 1-(fluoropentyl)indazole-
564 3-carboxylate).

565 (VII) FUB-NPB-22 (8-Quinoliny 1-(4-fluorobenzyl)indazole-
566 3-carboxylate).

567 (VIII) THJ (8-Quinoliny 1-pentylindazole-3-carboxamide).

568 (IX) Fluoro THJ (8-Quinoliny 1-(fluoropentyl)indazole-3-
569 carboxamide).

570 k. Naphthylindolecarboxylates and
571 Naphthylindazolecarboxylates.—Any compound containing a
572 naphthylindole carboxylate or naphthylindazole carboxylate
573 structure, with or without substitution on the indole or
574 indazole ring to any extent, whether or not substituted on the
575 naphthyl ring to any extent, including, but not limited to:

HB 1345

2021

576 (I) NM-2201 (1-Naphthalenyl 1-(5-fluoropentyl)indole-3-
577 carboxylate).

578 (II) SDB-005 (1-Naphthalenyl 1-pentylindazole-3-
579 carboxylate).

580 (III) Fluoro SDB-005 (1-Naphthalenyl 1-
581 (fluoropentyl)indazole-3-carboxylate).

582 (IV) FDU-PB-22 (1-Naphthalenyl 1-(4-fluorobenzyl)indole-3-
583 carboxylate).

584 (V) 3-CAF (2-Naphthalenyl 1-(2-fluorophenyl)indazole-3-
585 carboxylate).

586 1. Naphthylindole carboxamides and Naphthylindazole
587 carboxamides.—Any compound containing a naphthylindole
588 carboxamide or naphthylindazole carboxamide structure, with or
589 without substitution on the indole or indazole ring to any
590 extent, whether or not substituted on the naphthyl ring to any
591 extent, including, but not limited to:

592 (I) NNEI (N-Naphthalen-1-yl 1-pentylindole-3-carboxamide).

593 (II) Fluoro-NNEI (N-Naphthalen-1-yl 1-
594 (fluoropentyl)indole-3-carboxamide).

595 (III) Chloro-NNEI (N-Naphthalen-1-yl 1-
596 (chloropentyl)indole-3-carboxamide).

597 (IV) MN-18 (N-Naphthalen-1-yl 1-pentylindazole-3-
598 carboxamide).

599 (V) Fluoro MN-18 (N-Naphthalen-1-yl 1-
600 (fluoropentyl)indazole-3-carboxamide).

601 m. Alkylcarbonyl indole carboxamides, Alkylcarbonyl
602 indazole carboxamides, Alkylcarbonyl indole carboxylates, and
603 Alkylcarbonyl indazole carboxylates.—Any compound containing an
604 alkylcarbonyl group, including 1-amino-3-methyl-1-oxobutan-2-yl,
605 1-methoxy-3-methyl-1-oxobutan-2-yl, 1-amino-1-oxo-3-
606 phenylpropan-2-yl, 1-methoxy-1-oxo-3-phenylpropan-2-yl, with an
607 indole carboxamide, indazole carboxamide, indole carboxylate, or
608 indazole carboxylate, with or without substitution on the indole
609 or indazole ring to any extent, whether or not substituted on
610 the alkylcarbonyl group to any extent, including, but not
611 limited to:

612 (I) ADBICA, (N-(1-Amino-3,3-dimethyl-1-oxobutan-2-yl)-1-
613 pentylindole-3-carboxamide).

614 (II) Fluoro ADBICA (N-(1-Amino-3,3-dimethyl-1-oxobutan-2-
615 yl)-1-(fluoropentyl)indole-3-carboxamide).

616 (III) Fluoro ABICA (N-(1-Amino-3-methyl-1-oxobutan-2-yl)-
617 1-(fluoropentyl)indole-3-carboxamide).

618 (IV) AB-PINACA (N-(1-Amino-3-methyl-1-oxobutan-2-yl)-1-
619 pentylindazole-3-carboxamide).

620 (V) Fluoro AB-PINACA (N-(1-Amino-3-methyl-1-oxobutan-2-
621 yl)-1-(fluoropentyl)indazole-3-carboxamide).

622 (VI) ADB-PINACA (N-(1-Amino-3,3-dimethyl-1-oxobutan-2-yl)-
623 1-pentylindazole-3-carboxamide).

624 (VII) Fluoro ADB-PINACA (N-(1-Amino-3,3-dimethyl-1-
625 oxobutan-2-yl)-1-(fluoropentyl)indazole-3-carboxamide).

HB 1345

2021

- 626 (VIII) AB-FUBINACA (N-(1-Amino-3-methyl-1-oxobutan-2-yl)-
627 1-(4-fluorobenzyl)indazole-3-carboxamide).
- 628 (IX) ADB-FUBINACA (N-(1-Amino-3,3-dimethyl-1-oxobutan-2-
629 yl)-1-(4-fluorobenzyl)indazole-3-carboxamide).
- 630 (X) AB-CHMINACA (N-(1-Amino-3-methyl-1-oxobutan-2-yl)-1-
631 (cyclohexylmethyl)indazole-3-carboxamide).
- 632 (XI) MA-CHMINACA (N-(1-Methoxy-3-methyl-1-oxobutan-2-yl)-
633 1-(cyclohexylmethyl)indazole-3-carboxamide).
- 634 (XII) MAB-CHMINACA (N-(1-Amino-3,3-dimethyl-1-oxobutan-2-
635 yl)-1-(cyclohexylmethyl)indazole-3-carboxamide).
- 636 (XIII) AMB (N-(1-Methoxy-3-methyl-1-oxobutan-2-yl)-1-
637 pentylindazole-3-carboxamide).
- 638 (XIV) Fluoro-AMB (N-(1-Methoxy-3-methyl-1-oxobutan-2-yl)-
639 1-(fluoropentyl)indazole-3-carboxamide).
- 640 (XV) FUB-AMB (N-(1-Methoxy-3-methyl-1-oxobutan-2-yl)-1-(4-
641 fluorobenzyl)indazole-3-carboxamide).
- 642 (XVI) MDMB-CHMINACA (N-(1-Methoxy-3,3-dimethyl-1-oxobutan-
643 2-yl)-1-(cyclohexylmethyl)indazole-3-carboxamide).
- 644 (XVII) MDMB-FUBINACA (N-(1-Methoxy-3,3-dimethyl-1-
645 oxobutan-2-yl)-1-(4-fluorobenzyl)indazole-3-carboxamide).
- 646 (XVIII) MDMB-CHMICA (N-(1-Methoxy-3,3-dimethyl-1-oxobutan-
647 2-yl)-1-(cyclohexylmethyl)indole-3-carboxamide).
- 648 (XIX) PX-1 (N-(1-Amino-1-oxo-3-phenylpropan-2-yl)-1-(5-
649 fluoropentyl)indole-3-carboxamide).
- 650 (XX) PX-2 (N-(1-Amino-1-oxo-3-phenylpropan-2-yl)-1-(5-

651 fluoropentyl) indazole-3-carboxamide).

652 (XXI) PX-3 (N-(1-Amino-1-oxo-3-phenylpropan-2-yl)-1-
653 (cyclohexylmethyl) indazole-3-carboxamide).

654 (XXII) PX-4 (N-(1-Amino-1-oxo-3-phenylpropan-2-yl)-1-(4-
655 fluorobenzyl) indazole-3-carboxamide).

656 (XXIII) MO-CHMINACA (N-(1-Methoxy-3,3-dimethyl-1-oxobutan-
657 2-yl)-1-(cyclohexylmethyl) indazole-3-carboxylate).

658 n. Cumylindolecarboxamides and Cumylindazolecarboxamides.—
659 Any compound containing a N-(2-phenylpropan-2-yl) indole
660 carboxamide or N-(2-phenylpropan-2-yl) indazole carboxamide
661 structure, with or without substitution on the indole or
662 indazole ring to any extent, whether or not substituted on the
663 phenyl ring of the cumyl group to any extent, including, but not
664 limited to:

665 (I) CUMYL-PICA (N-(2-Phenylpropan-2-yl)-1-pentylindole-3-
666 carboxamide).

667 (II) Fluoro CUMYL-PICA (N-(2-Phenylpropan-2-yl)-1-
668 (fluoropentyl) indole-3-carboxamide).

669 o. Other Synthetic Cannabinoids.—Any material, compound,
670 mixture, or preparation that contains any quantity of a
671 Synthetic Cannabinoid, as described in sub-subparagraphs a.-n.:

672 (I) With or without modification or replacement of a
673 carbonyl, carboxamide, alkylene, alkyl, or carboxylate linkage
674 between either two core rings, or linkage between a core ring
675 and group structure, with or without the addition of a carbon or

676 replacement of a carbon;

677 (II) With or without replacement of a core ring or group

678 structure, whether or not substituted on the ring or group

679 structures to any extent; and

680 (III) Is a cannabinoid receptor agonist, unless

681 specifically excepted or unless listed in another schedule or

682 contained within a pharmaceutical product approved by the United

683 States Food and Drug Administration.

684 191. Substituted Cathinones.—Unless specifically excepted,

685 listed in another schedule, or contained within a pharmaceutical

686 product approved by the United States Food and Drug

687 Administration, any material, compound, mixture, or preparation,

688 including its salts, isomers, esters, or ethers, and salts of

689 isomers, esters, or ethers, whenever the existence of such salts

690 is possible within any of the following specific chemical

691 designations:

692 a. Any compound containing a 2-amino-1-phenyl-1-propanone

693 structure;

694 b. Any compound containing a 2-amino-1-naphthyl-1-

695 propanone structure; or

696 c. Any compound containing a 2-amino-1-thiophenyl-1-

697 propanone structure,

698

699 whether or not the compound is further modified:

700 (I) With or without substitution on the ring system to any

701 extent with alkyl, alkylthio, thio, fused alkylenedioxy, alkoxy,
 702 haloalkyl, hydroxyl, nitro, fused furan, fused benzofuran, fused
 703 dihydrofuran, fused tetrahydropyran, fused alkyl ring, or halide
 704 substituents;

705 (II) With or without substitution at the 3-propanone
 706 position with an alkyl substituent or removal of the methyl
 707 group at the 3-propanone position;

708 (III) With or without substitution at the 2-amino nitrogen
 709 atom with alkyl, dialkyl, acetyl, or benzyl groups, whether or
 710 not further substituted in the ring system; or

711 (IV) With or without inclusion of the 2-amino nitrogen
 712 atom in a cyclic structure, including, but not limited to:

- 713 (A) Methcathinone.
- 714 (B) Ethcathinone.
- 715 (C) Methylone (3,4-Methylenedioxy-methcathinone).
- 716 (D) 2,3-Methylenedioxy-methcathinone.
- 717 (E) MDPV (3,4-Methylenedioxy-pyrovalerone).
- 718 (F) Methylmethcathinone.
- 719 (G) Methoxymethcathinone.
- 720 (H) Fluoromethcathinone.
- 721 (I) Methylethcathinone.
- 722 (J) Butylone (3,4-Methylenedioxy-alpha-
 723 methylaminobutyrophenone).
- 724 (K) Ethylone (3,4-Methylenedioxy-N-ethylcathinone).
- 725 (L) BMDP (3,4-Methylenedioxy-N-benzylcathinone).

- 726 (M) Naphyrone (Naphthylpyrovalerone).
- 727 (N) Bromomethcathinone.
- 728 (O) Buphedrone (alpha-Methylaminobutyrophenone).
- 729 (P) Eutylone (3,4-Methylenedioxy-alpha-
- 730 ethylaminobutyrophenone).
- 731 (Q) Dimethylcathinone.
- 732 (R) Dimethylmethcathinone.
- 733 (S) Pentylone (3,4-Methylenedioxy-alpha-
- 734 methylaminovalerophenone).
- 735 (T) Pentedrone (alpha-Methylaminovalerophenone).
- 736 (U) MDPPP (3,4-Methylenedioxy-alpha-
- 737 pyrrolidinopropiophenone).
- 738 (V) MDPBP (3,4-Methylenedioxy-alpha-
- 739 pyrrolidinobutyrophenone).
- 740 (W) MPPP (Methyl-alpha-pyrrolidinopropiophenone).
- 741 (X) PPP (Pyrrolidinopropiophenone).
- 742 (Y) PVP (Pyrrolidinovalerophenone) or
- 743 (Pyrrolidinopentiophenone).
- 744 (Z) MOPPP (Methoxy-alpha-pyrrolidinopropiophenone).
- 745 (AA) MPHP (Methyl-alpha-pyrrolidinohexanophenone).
- 746 (BB) F-MABP (Fluoromethylaminobutyrophenone).
- 747 (CC) Me-EABP (Methylethylaminobutyrophenone).
- 748 (DD) PBP (Pyrrolidinobutyrophenone).
- 749 (EE) MeO-PBP (Methoxypyrrolidinobutyrophenone).
- 750 (FF) Et-PBP (Ethylpyrrolidinobutyrophenone).

751 (GG) 3-Me-4-MeO-MCAT (3-Methyl-4-Methoxymethcathinone).
 752 (HH) Dimethylone (3,4-Methylenedioxy-N,N-
 753 dimethylcathinone).
 754 (II) 3,4-Methylenedioxy-N,N-diethylcathinone.
 755 (JJ) 3,4-Methylenedioxy-N-acetylcathinone.
 756 (KK) 3,4-Methylenedioxy-N-acetylmethcathinone.
 757 (LL) 3,4-Methylenedioxy-N-acetylethcathinone.
 758 (MM) Methylbuphedrone (Methyl-alpha-
 759 methylaminobutyrophenone).
 760 (NN) Methyl-alpha-methylaminohexanophenone.
 761 (OO) N-Ethyl-N-methylcathinone.
 762 (PP) PHP (Pyrrolidinohexanophenone).
 763 (QQ) PV8 (Pyrrolidinoheptanophenone).
 764 (RR) Chloromethcathinone.
 765 (SS) 4-Bromo-2,5-dimethoxy-alpha-aminoacetophenone.
 766 192. Substituted Phenethylamines.—Unless specifically
 767 excepted or unless listed in another schedule, or contained
 768 within a pharmaceutical product approved by the United States
 769 Food and Drug Administration, any material, compound, mixture,
 770 or preparation, including its salts, isomers, esters, or ethers,
 771 and salts of isomers, esters, or ethers, whenever the existence
 772 of such salts is possible within any of the following specific
 773 chemical designations, any compound containing a phenethylamine
 774 structure, without a beta-keto group, and without a benzyl group
 775 attached to the amine group, whether or not the compound is

776 further modified with or without substitution on the phenyl ring
777 to any extent with alkyl, alkylthio, nitro, alkoxy, thio,
778 halide, fused alkylenedioxy, fused furan, fused benzofuran,
779 fused dihydrofuran, or fused tetrahydropyran substituents,
780 whether or not further substituted on a ring to any extent, with
781 or without substitution at the alpha or beta position by any
782 alkyl substituent, with or without substitution at the nitrogen
783 atom, and with or without inclusion of the 2-amino nitrogen atom
784 in a cyclic structure, including, but not limited to:

- 785 a. 2C-B (4-Bromo-2,5-dimethoxyphenethylamine).
- 786 b. 2C-E (4-Ethyl-2,5-dimethoxyphenethylamine).
- 787 c. 2C-T-4 (4-Isopropylthio-2,5-dimethoxyphenethylamine).
- 788 d. 2C-C (4-Chloro-2,5-dimethoxyphenethylamine).
- 789 e. 2C-T (4-Methylthio-2,5-dimethoxyphenethylamine).
- 790 f. 2C-T-2 (4-Ethylthio-2,5-dimethoxyphenethylamine).
- 791 g. 2C-T-7 (4-(n)-Propylthio-2,5-dimethoxyphenethylamine).
- 792 h. 2C-I (4-Iodo-2,5-dimethoxyphenethylamine).
- 793 i. 2C-D (4-Methyl-2,5-dimethoxyphenethylamine).
- 794 j. 2C-H (2,5-Dimethoxyphenethylamine).
- 795 k. 2C-N (4-Nitro-2,5-dimethoxyphenethylamine).
- 796 l. 2C-P (4-(n)-Propyl-2,5-dimethoxyphenethylamine).
- 797 m. MDMA (3,4-Methylenedioxyamphetamine).
- 798 n. MBDB (Methylbenzodioxolylbutanamine) or (3,4-
799 Methylenedioxy-N-methylbutanamine).
- 800 o. MDA (3,4-Methylenedioxyamphetamine).

- 801 p. 2,5-Dimethoxyamphetamine.
- 802 q. Fluoroamphetamine.
- 803 r. Fluoromethamphetamine.
- 804 s. MDEA (3,4-Methylenedioxy-N-ethylamphetamine).
- 805 t. DOB (4-Bromo-2,5-dimethoxyamphetamine).
- 806 u. DOC (4-Chloro-2,5-dimethoxyamphetamine).
- 807 v. DOET (4-Ethyl-2,5-dimethoxyamphetamine).
- 808 w. DOI (4-Iodo-2,5-dimethoxyamphetamine).
- 809 x. DOM (4-Methyl-2,5-dimethoxyamphetamine).
- 810 y. PMA (4-Methoxyamphetamine).
- 811 z. N-Ethylamphetamine.
- 812 aa. 3,4-Methylenedioxy-N-hydroxyamphetamine.
- 813 bb. 5-Methoxy-3,4-methylenedioxyamphetamine.
- 814 cc. PMMA (4-Methoxymethamphetamine).
- 815 dd. N,N-Dimethylamphetamine.
- 816 ee. 3,4,5-Trimethoxyamphetamine.
- 817 ff. 4-APB (4-(2-Aminopropyl)benzofuran).
- 818 gg. 5-APB (5-(2-Aminopropyl)benzofuran).
- 819 hh. 6-APB (6-(2-Aminopropyl)benzofuran).
- 820 ii. 7-APB (7-(2-Aminopropyl)benzofuran).
- 821 jj. 4-APDB (4-(2-Aminopropyl)-2,3-dihydrobenzofuran).
- 822 kk. 5-APDB (5-(2-Aminopropyl)-2,3-dihydrobenzofuran).
- 823 ll. 6-APDB (6-(2-Aminopropyl)-2,3-dihydrobenzofuran).
- 824 mm. 7-APDB (7-(2-Aminopropyl)-2,3-dihydrobenzofuran).
- 825 nn. 4-MAPB (4-(2-Methylaminopropyl)benzofuran).

- 826 oo. 5-MAPB (5-(2-Methylaminopropyl)benzofuran).
- 827 pp. 6-MAPB (6-(2-Methylaminopropyl)benzofuran).
- 828 qq. 7-MAPB (7-(2-Methylaminopropyl)benzofuran).
- 829 rr. 5-EAPB (5-(2-Ethylaminopropyl)benzofuran).
- 830 ss. 5-MAPDB (5-(2-Methylaminopropyl)-2,3-
- 831 dihydrobenzofuran),

832

833 which does not include phenethylamine, mescaline as described in

834 subparagraph 20., substituted cathinones as described in

835 subparagraph 191., N-Benzyl phenethylamine compounds as

836 described in subparagraph 193., or methamphetamine as described

837 in subparagraph (2)(c)5.

838 193. N-Benzyl Phenethylamine Compounds.—Unless

839 specifically excepted or unless listed in another schedule, or

840 contained within a pharmaceutical product approved by the United

841 States Food and Drug Administration, any material, compound,

842 mixture, or preparation, including its salts, isomers, esters,

843 or ethers, and salts of isomers, esters, or ethers, whenever the

844 existence of such salts is possible within any of the following

845 specific chemical designations, any compound containing a

846 phenethylamine structure without a beta-keto group, with

847 substitution on the nitrogen atom of the amino group with a

848 benzyl substituent, with or without substitution on the phenyl

849 or benzyl ring to any extent with alkyl, alkoxy, thio,

850 alkylthio, halide, fused alkylenedioxy, fused furan, fused

851 benzofuran, or fused tetrahydropyran substituents, whether or
852 not further substituted on a ring to any extent, with or without
853 substitution at the alpha position by any alkyl substituent,
854 including, but not limited to:

855 a. 25B-NBOMe (4-Bromo-2,5-dimethoxy-[N-(2-
856 methoxybenzyl)]phenethylamine).

857 b. 25B-NBOH (4-Bromo-2,5-dimethoxy-[N-(2-
858 hydroxybenzyl)]phenethylamine).

859 c. 25B-NBF (4-Bromo-2,5-dimethoxy-[N-(2-
860 fluorobenzyl)]phenethylamine).

861 d. 25B-NBMD (4-Bromo-2,5-dimethoxy-[N-(2,3-
862 methylenedioxybenzyl)]phenethylamine).

863 e. 25I-NBOMe (4-Iodo-2,5-dimethoxy-[N-(2-
864 methoxybenzyl)]phenethylamine).

865 f. 25I-NBOH (4-Iodo-2,5-dimethoxy-[N-(2-
866 hydroxybenzyl)]phenethylamine).

867 g. 25I-NBF (4-Iodo-2,5-dimethoxy-[N-(2-
868 fluorobenzyl)]phenethylamine).

869 h. 25I-NBMD (4-Iodo-2,5-dimethoxy-[N-(2,3-
870 methylenedioxybenzyl)]phenethylamine).

871 i. 25T2-NBOMe (4-Methylthio-2,5-dimethoxy-[N-(2-
872 methoxybenzyl)]phenethylamine).

873 j. 25T4-NBOMe (4-Isopropylthio-2,5-dimethoxy-[N-(2-
874 methoxybenzyl)]phenethylamine).

875 k. 25T7-NBOMe (4-(n)-Propylthio-2,5-dimethoxy-[N-(2-

876 methoxybenzyl)]phenethylamine) .

877 1. 25C-NBOMe (4-Chloro-2,5-dimethoxy-[N-(2-
878 methoxybenzyl)]phenethylamine) .

879 m. 25C-NBOH (4-Chloro-2,5-dimethoxy-[N-(2-
880 hydroxybenzyl)]phenethylamine) .

881 n. 25C-NBF (4-Chloro-2,5-dimethoxy-[N-(2-
882 fluorobenzyl)]phenethylamine) .

883 o. 25C-NBMD (4-Chloro-2,5-dimethoxy-[N-(2,3-
884 methylenedioxybenzyl)]phenethylamine) .

885 p. 25H-NBOMe (2,5-Dimethoxy-[N-(2-
886 methoxybenzyl)]phenethylamine) .

887 q. 25H-NBOH (2,5-Dimethoxy-[N-(2-
888 hydroxybenzyl)]phenethylamine) .

889 r. 25H-NBF (2,5-Dimethoxy-[N-(2-
890 fluorobenzyl)]phenethylamine) .

891 s. 25D-NBOMe (4-Methyl-2,5-dimethoxy-[N-(2-
892 methoxybenzyl)]phenethylamine) ,

893

894 which does not include substituted cathinones as described in
895 subparagraph 191.

896 194. Substituted Tryptamines.—Unless specifically excepted
897 or unless listed in another schedule, or contained within a
898 pharmaceutical product approved by the United States Food and
899 Drug Administration, any material, compound, mixture, or
900 preparation containing a 2-(1H-indol-3-yl)ethanamine, for

901 example tryptamine, structure with or without mono- or di-
902 substitution of the amine nitrogen with alkyl or alkenyl groups,
903 or by inclusion of the amino nitrogen atom in a cyclic
904 structure, whether or not substituted at the alpha position with
905 an alkyl group, whether or not substituted on the indole ring to
906 any extent with any alkyl, alkoxy, halo, hydroxyl, or acetoxy
907 groups, including, but not limited to:

- 908 a. Alpha-Ethyltryptamine.
- 909 b. Bufotenine.
- 910 c. DET (Diethyltryptamine).
- 911 d. DMT (Dimethyltryptamine).
- 912 e. MET (N-Methyl-N-ethyltryptamine).
- 913 f. DALT (N,N-Diallyltryptamine).
- 914 g. EiPT (N-Ethyl-N-isopropyltryptamine).
- 915 h. MiPT (N-Methyl-N-isopropyltryptamine).
- 916 i. 5-Hydroxy-AMT (5-Hydroxy-alpha-methyltryptamine).
- 917 j. 5-Hydroxy-N-methyltryptamine.
- 918 k. 5-MeO-MiPT (5-Methoxy-N-methyl-N-isopropyltryptamine).
- 919 l. 5-MeO-AMT (5-Methoxy-alpha-methyltryptamine).
- 920 m. Methyltryptamine.
- 921 n. 5-MeO-DMT (5-Methoxy-N,N-dimethyltryptamine).
- 922 o. 5-Me-DMT (5-Methyl-N,N-dimethyltryptamine).
- 923 p. 5-MeO-DiPT (5-Methoxy-N,N-Diisopropyltryptamine).
- 924 q. DiPT (N,N-Diisopropyltryptamine).
- 925 r. DPT (N,N-Dipropyltryptamine).

- 926 s. 4-Hydroxy-DiPT (4-Hydroxy-N,N-diisopropyltryptamine).
- 927 t. 5-MeO-DALT (5-Methoxy-N,N-Diallyltryptamine).
- 928 u. 4-AcO-DMT (4-Acetoxy-N,N-dimethyltryptamine).
- 929 v. 4-AcO-DiPT (4-Acetoxy-N,N-diisopropyltryptamine).
- 930 w. 4-Hydroxy-DET (4-Hydroxy-N,N-diethyltryptamine).
- 931 x. 4-Hydroxy-MET (4-Hydroxy-N-methyl-N-ethyltryptamine).
- 932 y. 4-Hydroxy-MiPT (4-Hydroxy-N-methyl-N-
- 933 isopropyltryptamine).
- 934 z. Methyl-alpha-ethyltryptamine.
- 935 aa. Bromo-DALT (Bromo-N,N-diallyltryptamine),

936
 937 which does not include tryptamine, psilocyn as described in
 938 subparagraph 34., or psilocybin as described in subparagraph 33.

939 195. Substituted Phenylcyclohexylamines.—Unless
 940 specifically excepted or unless listed in another schedule, or
 941 contained within a pharmaceutical product approved by the United
 942 States Food and Drug Administration, any material, compound,
 943 mixture, or preparation containing a phenylcyclohexylamine
 944 structure, with or without any substitution on the phenyl ring,
 945 any substitution on the cyclohexyl ring, any replacement of the
 946 phenyl ring with a thiophenyl or benzothiophenyl ring, with or
 947 without substitution on the amine with alkyl, dialkyl, or alkoxy
 948 substituents, inclusion of the nitrogen in a cyclic structure,
 949 or any combination of the above, including, but not limited to:

- 950 a. BTCP (Benzothiophenylcyclohexylpiperidine) or BCP

- 951 (Benocyclidine).
- 952 b. PCE (N-Ethyl-1-phenylcyclohexylamine) (Ethylamine analog
- 953 of phencyclidine).
- 954 c. PCPY (N-(1-Phenylcyclohexyl)-pyrrolidine) (Pyrrolidine
- 955 analog of phencyclidine).
- 956 d. PCPr (Phenylcyclohexylpropylamine).
- 957 e. TCP (1-[1-(2-Thienyl)-cyclohexyl]-piperidine) (Thiophene
- 958 analog of phencyclidine).
- 959 f. PCEEA (Phenylcyclohexyl (ethoxyethylamine)).
- 960 g. PCMPA (Phenylcyclohexyl (methoxypropylamine)).
- 961 h. Methoxetamine.
- 962 i. 3-Methoxy-PCE ((3-Methoxyphenyl)cyclohexylethylamine).
- 963 j. Bromo-PCP ((Bromophenyl)cyclohexylpiperidine).
- 964 k. Chloro-PCP ((Chlorophenyl)cyclohexylpiperidine).
- 965 l. Fluoro-PCP ((Fluorophenyl)cyclohexylpiperidine).
- 966 m. Hydroxy-PCP ((Hydroxyphenyl)cyclohexylpiperidine).
- 967 n. Methoxy-PCP ((Methoxyphenyl)cyclohexylpiperidine).
- 968 o. Methyl-PCP ((Methylphenyl)cyclohexylpiperidine).
- 969 p. Nitro-PCP ((Nitrophenyl)cyclohexylpiperidine).
- 970 q. Oxo-PCP ((Oxophenyl)cyclohexylpiperidine).
- 971 r. Amino-PCP ((Aminophenyl)cyclohexylpiperidine).
- 972 196. W-15, 4-chloro-N-[1-(2-phenylethyl)-2-
- 973 piperidinylidene]-benzenesulfonamide.
- 974 197. W-18, 4-chloro-N-[1-[2-(4-nitrophenyl)ethyl]-2-
- 975 piperidinylidene]-benzenesulfonamide.

HB 1345

2021

- 976 | 198. AH-7921, 3,4-dichloro-N-[[1-
 977 | (dimethylamino)cyclohexyl]methyl]-benzamide.
 978 | 199. U47700, trans-3,4-dichloro-N-[2-
 979 | (dimethylamino)cyclohexyl]-N-methyl-benzamide.
 980 | 200. MT-45, 1-cyclohexyl-4-(1,2-diphenylethyl)-piperazine,
 981 | dihydrochloride.
 982 | Section 2. This act shall take effect upon becoming a law.